Achaogen Inc. (AKAO) COO Blake Wise Sells 3,632 Shares
Achaogen Inc. (NASDAQ:AKAO) COO Blake Wise sold 3,632 shares of the company’s stock in a transaction on Tuesday, September 27th. The stock was sold at an average price of $4.30, for a total transaction of $15,617.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Achaogen Inc. (NASDAQ:AKAO) opened at 4.79 on Monday. Achaogen Inc. has a 12-month low of $2.59 and a 12-month high of $6.50. The stock’s market capitalization is $127.79 million. The firm’s 50-day moving average is $4.13 and its 200 day moving average is $3.68.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.20. The company earned $9.14 million during the quarter, compared to analysts’ expectations of $5.58 million. Achaogen had a negative return on equity of 118.45% and a negative net margin of 209.23%. Achaogen’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) EPS. On average, equities research analysts forecast that Achaogen Inc. will post ($2.71) EPS for the current fiscal year.
Several equities analysts recently weighed in on AKAO shares. Zacks Investment Research upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Thursday, August 25th. Wedbush upgraded shares of Achaogen from a “neutral” rating to an “outperform” rating and increased their price target for the company from $7.00 to $10.00 in a research report on Tuesday, June 14th. Needham & Company LLC restated a “hold” rating on shares of Achaogen in a research report on Tuesday, August 9th. Finally, SunTrust Banks Inc. restated a “buy” rating and set a $10.00 price target on shares of Achaogen in a research report on Monday, September 26th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Achaogen has a consensus rating of “Hold” and a consensus price target of $8.17.
Several institutional investors have recently bought and sold shares of AKAO. Point72 Asset Management L.P. raised its position in Achaogen by 241.4% in the second quarter. Point72 Asset Management L.P. now owns 890,000 shares of the biopharmaceutical company’s stock valued at $3,373,000 after buying an additional 629,309 shares in the last quarter. A.R.T. Advisors LLC bought a new position in Achaogen during the second quarter valued at about $142,000. Eagle Global Advisors LLC raised its position in Achaogen by 55.4% in the second quarter. Eagle Global Advisors LLC now owns 38,749 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 13,812 shares in the last quarter. Polar Capital LLP bought a new position in Achaogen during the second quarter valued at about $379,000. Finally, Bridgeway Capital Management Inc. raised its position in Achaogen by 13.2% in the second quarter. Bridgeway Capital Management Inc. now owns 156,185 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 18,235 shares in the last quarter. 56.84% of the stock is owned by hedge funds and other institutional investors.
Achaogen Company Profile
Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).
Receive News & Stock Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related stocks with our FREE daily email newsletter.